Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Infliximab + Talquetamab-tgvs |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Infliximab | Remicade | Avakine|cA2|Remsima | Remicade (infliximab) is a monoclonal antibody that targets tumor necrosis factor alpha (TNF-alpha), potentially resulting in increased or decreased apoptosis (NCI Drug Dictionary). | |
| Talquetamab-tgvs | Talvey | JNJ64407564|JNJ 64407564|JNJ-64407564 | CD3 Antibody 126 | Talvey (talquetamab-tgvs) is a bispecific antibody that targets CD3 and GPRC5D, potentially resulting in increased immune response against GPRC5D-expressing tumor cells (PMID: 32040549). Talvey (talquetamab-tgvs) is FDA-approved for use in adult patients with relapsed or refractory multiple myeloma who have received four or more prior lines of therapy (FDA.gov). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07657312 | Phase II | Talquetamab-tgvs Teclistamab Infliximab + Teclistamab Infliximab + Talquetamab-tgvs | Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory Myeloma | Not yet recruiting | USA | 0 |